Great [C-diff] News

Here it is! The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have released updated guidelines for treatment of c-diff. And Dificid just rose to the top. While some of you may be saying “Duh! We already knew Dificid is better,” this is important because doctors reference these guidelines when determining treatment. It may also mean more insurance companies cover it as the first line of treatment rather than waiting for people to fail Vancomycin. New guidelines include:

➡️ For patients with an initial C. difficile episode, fidaxomicin [that’s Dificid] is recommended rather than a standard course of vancomycin.

➡️ For patients with recurrent C. difficile episodes, a standard or extended-pulsed regimen of fidaxomicin should be used rather than a standard course of vancomycin.

➡️ For patients with a recurrent C. difficile episode within the past 6 months, bezlotoxumab [that’s Zinplava] and standard-of-care antibiotics should be used rather than standard-of-care antibiotics alone.

Leave a comment

Filed under C-Diff

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s